Global Burden of Male Infertility From 1990 to 2021: Prevalence and DALYs Across 204 Countries
Andrologia · 2025-01 · 2025 (1)
DOI: 10.1155/and/8763243 ↗Abstract
Background The growing burden of male infertility has emerged as a critical public health concern. However, current epidemiological evidence remains limited and inconsistent. This study is among the first to analyze the global disease burden of male infertility using Global Burden of Disease (GBD) 2021, providing critical evidence to inform policy development. Objective Using the GBD 2021 dataset, we assessed 30‐year trends (1990–2021) in male infertility epidemiology worldwide. These findings provide critical insights for evidence‐based policy making and resource allocation in global reproductive health. Methods Utilizing data from the GBD 2021 dataset, we evaluated the burden of male infertility in the reproductive‐age population (15–49 years). Our analysis encompassed prevalence, disability‐adjusted life years (DALYs), and their associated 95% uncertainty intervals (UIs), with stratification by age group, geographic region, and country from 1990 to 2021. We investigated associations with socioeconomic determinants, particularly the sociodemographic index (SDI), using Spearman’s rank correlation analysis. Temporal patterns were assessed through the calculation of estimated annual percentage changes (EAPCs). Results In 2021, the global prevalence of male infertility reached 55,000,818 cases, corresponding to an age‐standardized prevalence rate (ASPR) of 2737.42 per 100,000 population. The condition accounted for 317,614 DALYs, with an age‐standardized DALY rate (ASDR) of 15.84 per 100,000 population. Geospatial analysis revealed substantial regional variation, with Eastern Europe demonstrating the highest burden of male infertility, while Australasia exhibited the lowest prevalence rates. Conclusion The study documents a sustained increase in male infertility prevalence among reproductive‐aged men worldwide from 1990 to 2021. Effective response strategies should combine medical innovation, health policy reforms, and equitable resource distribution to address this emerging public health priority.
EUVIMED